Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naïve People with Type 2 Diabetes: the ATOS Study

被引:0
作者
Gagik R. Galstyan
Amir Tirosh
Hernando Vargas-Uricoechea
Maria Aileen Mabunay
Mathieu Coudert
Mubarak Naqvi
Valerie Pilorget
Niaz Khan
机构
[1] Endocrinology Research Centre of Health Care Ministry of Russian Federation,Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer
[2] Tel Aviv University,Division of Endocrinology and Metabolism, Department of Internal Medicine
[3] Universidad del Cauca,undefined
[4] Sanofi,undefined
[5] Sanofi,undefined
[6] Sanofi,undefined
[7] Imperial College London Diabetes Centre,undefined
来源
Diabetes Therapy | 2022年 / 13卷
关键词
Basal insulin; Glycaemic control; Hypoglycaemia; Insulin glargine 300 U/mL; Real-world; Type 2 diabetes;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1187 / 1202
页数:15
相关论文
共 99 条
[1]  
Wu Y(2014)Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention Int J Med Sci 11 1185-1200
[2]  
Ding Y(2016)Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 44 million participants Lancet 387 1513-1530
[3]  
Tanaka Y(2009)Common genetic variation near melatonin receptor MTNR1B contributes to raised plasma glucose and increased risk of type 2 diabetes among Indian Asians and European Caucasians Diabetes 58 2703-2708
[4]  
Zhang W(2015)Need for ethnic-specific guidelines for prevention, diagnosis, and management of type 2 diabetes in South Asians Diabetes Technol Ther 17 435-439
[5]  
Chambers JC(2016)Socioeconomic factors relating to diabetes and its management in India J Diabetes 8 12-23
[6]  
Zhang W(2014)Diabetes in South Asians: is the phenotype different? Diabetes 63 53-55
[7]  
Zabaneh D(2018)Diabetes in South Asians: phenotype, clinical presentation, and natural history Curr Diabetes Rep 18 30-1860
[8]  
Shrivastava U(2014)U300, a novel long-acting insulin formulation Expert Opin Biol Ther 14 1849-867
[9]  
Misra A(2015)Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes Diabetes Obes Metab 17 859-621
[10]  
Shrivastava U(2020)Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naive people with type 2 diabetes: the EDITION AP randomized controlled trial Diabetes Obes Metab 22 612-2762